Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Alexian Brothers Neurosciences Institute Clinical Research
mi
from
Elk Grove Village, IL
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Alexian Brothers Neurosciences Institute Clinical Research
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Indiana University Department of Neurology
mi
from
Indianapolis, IN
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Indiana University Department of Neurology
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Neurological Clinical Research Institute (NCRI) Massachusetts General Hospital
mi
from
Boston, MA
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Neurological Clinical Research Institute (NCRI) Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Mayo Clinic, Department of Neurology
mi
from
Rochester, MN
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Mayo Clinic, Department of Neurology
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Neurological Associates of Albany, P. C.
mi
from
Albany, NY
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Neurological Associates of Albany, P. C.
mi
from
Albany, NY
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Integrative Clinical Trials, LLC
mi
from
Brooklyn, NY
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Integrative Clinical Trials, LLC
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
UNC Department of Neurology, Physicians Office Building
mi
from
Chapel Hill, NC
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
UNC Department of Neurology, Physicians Office Building
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
University Hospitals Case Medical Center, Neurology Clinical Trials Unit
mi
from
Cleveland, OH
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
University Hospitals Case Medical Center, Neurology Clinical Trials Unit
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Hospital of the University of Pennsylvania, Department of Neurology
mi
from
Philadelphia, PA
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Hospital of the University of Pennsylvania, Department of Neurology
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
The Memory Clinic
mi
from
Bennington, VT
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
The Memory Clinic
mi
from
Bennington, VT
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
University of Virginia
mi
from
Charlottesville, VA
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Johns Hopkins University
mi
from
Baltimore, MD
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Rivers Wellness and Research Institute
mi
from
Oklahoma City, OK
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Rivers Wellness and Research Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
PRA Health Sciences Phase 2/3 Outpatient & CNS Clinic
mi
from
Salt Lake City, UT
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
PRA Health Sciences Phase 2/3 Outpatient & CNS Clinic
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated:  3/12/2018
Neuroscience Research Australia
mi
from
Randwick,
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status: Enrolling
Updated: 3/12/2018
Neuroscience Research Australia
mi
from
Randwick,
Click here to add this to my saved trials
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Status: Enrolling
Updated:  3/12/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI
Status: Enrolling
Updated: 3/12/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
Status: Enrolling
Updated:  3/12/2018
Stanford Hospital and Clinics
mi
from
Stanford, CA
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
Status: Enrolling
Updated: 3/12/2018
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Alabama -- Department of Neurology/Epilepsy Center
mi
from
Birmingham, AL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Alabama -- Department of Neurology/Epilepsy Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
North Alabama Neuroscience Research Associates
mi
from
Huntsville, AL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
North Alabama Neuroscience Research Associates
mi
from
Huntsville, AL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Neurology Clinic PC
mi
from
Northport, AL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Neurology Clinic PC
mi
from
Northport, AL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Barrow Neurological Institute
mi
from
Phoenix, AZ
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Clinical Trials, Inc.
mi
from
Little Rock, AR
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Clinical Trials, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
UCSD - Thornton Hospital
mi
from
La Jolla, CA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
UCSD - Thornton Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
West Los Angeles VA Healthcare Center
mi
from
Los Angeles, CA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
West Los Angeles VA Healthcare Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Delta Waves, INC
mi
from
Colorado Springs, CO
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Delta Waves, INC
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Colorado Department Of Neurology
mi
from
Denver, CO
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Colorado Department Of Neurology
mi
from
Denver, CO
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Florida-Shands/Jacksonville
mi
from
Jacksonville, FL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Florida-Shands/Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Miami
mi
from
Miami, FL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Lovelace Scientific Resources
mi
from
Sarasota, FL
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Lovelace Scientific Resources
mi
from
Sarasota, FL
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
McFarland Clinic, PC
mi
from
Ames, IA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
McFarland Clinic, PC
mi
from
Ames, IA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Kentucky
mi
from
Lexington, KY
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Mid-Atlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Mid-Atlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Henry Ford Hospital
mi
from
Detroit, MI
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
The Comprehensive Epilepsy Care Center For Children and Adults
mi
from
Chesterfield, MO
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
The Comprehensive Epilepsy Care Center For Children and Adults
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Beth Israel Med Ctr
mi
from
New York, NY
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Asheville Neurology Specialists, PA
mi
from
Asheville, NC
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Asheville Neurology Specialists, PA
mi
from
Asheville, NC
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Medical University of Ohio at Toledo
mi
from
Toledo, OH
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Medical University of Ohio at Toledo
mi
from
Toledo, OH
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Oregon Neurology PC
mi
from
Tualatin, OR
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Oregon Neurology PC
mi
from
Tualatin, OR
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
The Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Medical City Dallas Hospital
mi
from
Dallas, TX
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Medical City Dallas Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Neurological Clinic - Texas
mi
from
Dallas, TX
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Neurological Clinic - Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Memorial Hermann Hospital
mi
from
Houston, TX
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Memorial Hermann Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
University of Virginia Comprehensive Epilepsy Program
mi
from
Charlottesville, VA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
University of Virginia Comprehensive Epilepsy Program
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
VCU Medical Center
mi
from
Richmond, VA
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Hospital Italiano de Buenos Aires
mi
from
Capital Federal,
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Hospital Italiano de Buenos Aires
mi
from
Capital Federal,
Click here to add this to my saved trials
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated:  3/12/2018
Minnesota Epilepsy Group
mi
from
Saint Paul, MN
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)
Status: Enrolling
Updated: 3/12/2018
Minnesota Epilepsy Group
mi
from
Saint Paul, MN
Click here to add this to my saved trials